The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.
 
Carlo Palmieri
No Relationships to Disclose
 
Hannah M. Linden
No Relationships to Disclose
 
Stephen Birrell
Employment - HAVAH Therapeutics
Leadership - HAVAH Therapeutics
Stock and Other Ownership Interests - HAVAH Therapeutics
 
Elgene Lim
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Travel, Accommodations, Expenses - Lilly
 
Lee S. Schwartzberg
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Genentech; Helsinn Therapeutics; Lilly; Myriad Genetics; Napo Pharmaceuticals; Odonate Therapeutics; Pfizer; Spectrum Pharmaceuticals
Speakers' Bureau - Coherus Biosciences; Merck; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); Pfizer (Inst)
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Patrick Wayne Cobb
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Boston Scientific; crispr therapeutics; Intuitive Surgical; Johnson & Johnson; Medtronic; Merck; Pfizer (I); Siemens; Thermo Fisher Scientific; United Health Group
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Altor BioScience (Inst); Aptose Biosciences (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Decibel Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Galera Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocare (Inst); Ipsen (Inst); Isofol Medical (Inst); MEI Pharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); United Therapeutics (Inst); Viracta Therapeutics (Inst)
 
Kirti Jain
No Relationships to Disclose
 
Charles L. Vogel
Consulting or Advisory Role - Veru
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Stephen R. D. Johnston
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Expert Testimony - Novartis
 
Robert H. Getzenberg
Employment - Veru; Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru
Consulting or Advisory Role - Veru
 
K. Gary Barnette
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
Patents, Royalties, Other Intellectual Property - Veru
 
Mitchell S. Steiner
Employment - Veru
Leadership - Veru
Stock and Other Ownership Interests - Veru
Patents, Royalties, Other Intellectual Property - Veru
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Genomic Health; Immunomedics; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology; Seagen
 
Beth Overmoyer
No Relationships to Disclose